Targets › MCIR
1 program from 1 company in 1 trial: 1 Phase 2; Immunology.
Open in Phaseline: the race on MCIR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Palatin Technologies | PL8177 Melanocortin receptor agonist | MCIR | Phase 2 | Ulcerative Colitis | – |
Ulcerative Colitis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.